Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Forward Pharma Loses Appeals Bid to Collect U.S. Royalties on Biogen’s MS Drug Tecfidera

By Catherine Sbeglia | October 25, 2018

Earlier this week, Forward Pharma, a Danish biopharmaceutical company, announced that the U.S. Court of Appeals for the Federal Circuit upheld the decision of the Patent Trial and Appeal Board validated two patents covering Tecfidera (dimethyl fumarate), Biogen’s multiple sclerosis (MS) drug.

Dr. Claus Bo Svendsen, CEO of Forward commented, “We are disappointed with the Federal Circuit’s decision to affirm the decision of the PTAB. As we have indicated throughout the appeal process, under the Settlement and License Agreement with Biogen, a positive outcome from the Interference after exhaustion of all appeals is among the conditions that must be satisfied for future royalties from the net sales of Tecfidera in the United States to be payable to Forward.”

Forward expects to reduce operating expenses to match the current situation, and is currently considering further options and responses to the decision. The appeal of the decision in the European EP2801355 patent opposition is progressing as planned.

Last year, Biogen had agreed to pay $1.25 billion to Forward Pharma in exchange for an irrevocable license to all of the Forward’s intellectual property. 

Tecfidera was approved in the U.S. in 2013 for use in patients with MS and then by European regulators the following year.

(Source: GlobeNewswire)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE